IBD: CpG methylation in The TGF beta 1 and IL-6 genes is a biomarker for diagnosing IBD in children

BACKGROUND: Finding diagnostic markers that distinguish between Crohn's disease (CD) and ulcerative colitis (UC) remains a clinical challengeThe study was designed to assess whether the methylation markers of the transmutation growth factor beta 1 (TGF beta 1) and the interleukin 6 gene initiators had a diagnostic effectmethod: This study is a case-by-case control studyAll participants were children who were diagnosed before the age of 20 and were untreatedThere is no inflammatory bowel disease in the control patientsThe researchers conducted biochemical analysis of patient DNA from peripheral blood to identify methylation sites (CpGs) in the gene promoter regions of TGF beta 1 and interleukin 6Through the initial non-parametric single variable analysis, the multi-logical regression model is fittedA model with the best fit (Akaike information standard) and the strongest distinguishing capability (area under the curve (AUC)) was determinedresults: This study included a total of 67 CDs, 31 UC and 43 control patientsThe age distribution symmes of the 3 groups are similarMost CD patients have repathic colon disease (44.8%) and are in the inflammatory stage (88.1%)Most UC patients have a widespread (71%) and moderate disease (51.6%)Logistic regression analysis showed the following: there were 14 TGF beta 1CpG sites between CD and control patients (AUC s 0.94), 9 TGF beta1CpG sites between UC and control patients (AUC s 0.99), 3 TGF beta 1CpG sites between CD and UC (AUC s 0.81), and 6 TGF beta1G points to distinguish between colon CD and 1C1Conclusion: CpG methylation in TGF beta 1 gene promoters has a high ability to distinguish, recognize CDs and UC, and can be an important diagnostic marker